The pulmonology devices market shows strong growth potential from 2025 to 2035 because of rising worldwide respiratory disease occurrence and advanced medical technology development and the growing number of elderly patients. The management of asthma together with COPD and lung cancer and respiratory infections depends upon essential pulmonology devices. The forecast shows the market value starting from USD 1,703.2 million in 2025 as it will grow to USD 4,417.7 million by 2035 at a ten percent compound annual growth rate.
Market growth is being accelerated through the simultaneous rise of environmental contamination and smoking activities along with pulmonary health concerns emerging after the pandemic. The incorporation of portable spirometers and digital bronchoscopes combined with AI-enabled ventilators helps improve diagnosis methods and treatment activities.
The implementation of pulmonology devices faces storage obstacles because of exorbitant devices prices along with insurance coverage restrictions in addition to scarce access to pulmonology professionals in regions with meager economic resources. Companies in the market work to create cost-competitive home-use solutions and build strategic relationships with healthcare providers to deliver training and distribution services.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 1,703.2 million |
| Industry Value (2035F) | USD 4,417.7 million |
| CAGR (2025 to 2035) | 10% |
The pulmonology devices market has two major segments that include device types and end-user operations while diagnostic laboratories and hospital systems and home healthcare units show increasing market demand. The main device types included in the market consist of spirometers alongside bronchoscopes and inhalers as well as ventilators and sleep apnea devices. The market leadership of spirometers and inhalers becomes possible since these devices help identify and manage asthma and COPD in wide patient populations.
Hospitals provide the most extensive utilization of respiratory technologies because they possess the necessary specialized facilities to deliver advanced diagnostics through their integrated respiratory departments.
Home healthcare continues to grow because remote monitoring technology enhances patient care and patients increasingly prefer treatments outside traditional medical buildings. Healthcare providers focus on early diagnosis testing and non-hospital respiratory care systems to enhance patient health results and cut down on both patient and healthcare facility presence.
Explore FMI!
Book a free demo
North America retains dominating position across the pulmonology devices market due to high awareness, accessibility of advanced healthcare infrastructure, and rising demand for home respiratory care. Mobile diagnostic and therapy devices are primarily adopted in the USA and Canada.
Increase in the use of the aging population, favourable air quality regulations, and matured respiratory care systems around the read of the Europe market. Demand is led by Germany, France, and the UK through investments in non-invasive diagnostics and hospital-based respiratory therapies.
The global pulmonology devices market is witnessing the fastest growth in the Asia-Pacific region, which is driven by increasing urban air pollution, smoking prevalence, and growing healthcare infrastructure. Finally, at this late stage we doubt the global epidemiological value of additional action in these three leading respiratory-generating countries (China, India, Japan, and South Korea).
Challenge: Device Accessibility and Infrastructure Limitations
The pulmonary devices market is consistently inhibited by several unmet needs, including access to advanced respiratory devices in low-resource settings, inconsistent availability of healthcare infrastructure in some countries, and high-care intensity demand globally.
While the demand for pulmonology devices such as spirometers, nebulizers, CPAP/BiPAP machines and bronchoscopes are increasing, a number of regions around the globe, especially those in under-developed economies, do not have the clinical capacity or funding ability to deploy and maintain such equipment. Limited access to trained personnel, erratic power supply, and high cost of maintenance are also barriers to the use of advanced pulmonary diagnostic and therapeutic devices on a global scale.
Both in low- and middle-income markets, as well as in higher-income countries, sluggish approval timelines, cost containment demands and reimbursement uncertainties impede innovation and decrease the commercial attractiveness for novel respiratory devices.
Opportunity: Growth in Chronic Respiratory Conditions and Home-Based Care
The market is poised for solid growth owing to an increase in the occurrence of chronic respiratory conditions like COPD, asthma, pulmonary fibrosis, and sleep apnea. Recent increases in environmental pollution, urbanization, smoking rates, and aging populations drive a growing burden of disease that will need to be addressed with early diagnosis and long-term respiratory support. At a larger level, the trajectory toward the home and tele monitoring is reshaping how pulmonology devices will be used and delivered.
Manufacturers are stepping up to meet the challenge with portable spirometers, handheld nebulizers, wearable respiratory monitors and connected CPAP machines, patients can find both comfort and continuity of care at home. As remote monitoring finally goes mainstream, particularly in post-acute care and chronic disease management, demand for easy-to-use, connected pulmonary devices will rise, as will their use in all healthcare settings.
2020 to 2024 High attention towards respiratory diseases and diagnostics led to the growth of the pulmonology devices market. Hospitals escalated adoption of ventilators, pulse oximeters, and advanced imaging systems as patients turned more to at-home nebulizers and sleep therapy devices. Yet, the growing demand revealed global inequalities in device availability, oxygen infrastructure, and after-sale support, calling for more equitable access and scalable solutions.
From 2025 to 2035, the industry will be transformed by intelligent, connected pulmonology ecosystems with AI-enabled diagnostics, smart inhalation devices, and predictive monitoring. Real-time respiratory tracking, integrated care platforms and personalized treatment protocols will drive growth. New technologies like non-invasive gas exchange monitoring, digital bronchoscopy and adaptive airway pressure systems will raise the bar for accuracy and patient compliance.
The market will also be shaped by a greater focus on value-based care, respiratory wellness programs, and outpatient pulmonary rehabilitation, which will create opportunities for startups and established medtech firms to offer modular, patient-centric devices adapted to different populations.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Focus on the safety of devices, their rapid emergency use approval, and quality assurance. |
| Technological Advancements | Surge in ventilator innovation, portable nebulizers, and CPAP enhancements. |
| Sustainability Trends | Initial focus on device sterilization and single-use components. |
| Market Competition | Dominated by respiratory therapy companies and hospital equipment providers. |
| Industry Adoption | Widely used in critical care units, pulmonology departments, and home settings. |
| Consumer Preferences | Demand for easy-to-use, portable, and affordable respiratory aids. |
| Market Growth Drivers | Growth driven by rising chronic respiratory diseases and demand for non-invasive therapies. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Expansion into AI-assisted diagnostics, long-term device performance tracking, and remote usage regulation. |
| Technological Advancements | Growth in smart spirometry, digital bronchoscopy, cloud-based monitoring, and adaptive ventilation systems. |
| Sustainability Trends | Shift to eco-friendly materials, reusable filters, and energy-efficient home-use devices. |
| Market Competition | Entry of digital health startups, wearable device innovators, and remote care platforms. |
| Industry Adoption | Expanded use in primary care, community clinics, mobile health vans, and remote diagnostics hubs. |
| Consumer Preferences | Preference for connected, personalized, and integrated respiratory health management solutions. |
| Market Growth Drivers | Expansion fueled by digital transformation, aging demographics, and remote care integration. |
The United States pulmonology devices market is anticipated to grow tremendously owing to the high prevalence of chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma, the aging population and robust hospital infrastructure. The increased usage of home-based respiratory monitoring, portable spirometers, and smart devices built for inhalation, for example, is progressively changing the surroundings.
The adoption is further propelled by government funding for telepulmonology, integration of AI in diagnostic devices and reimbursement for non-invasive ventilation (NIV) therapies. Moreover, consistent demand is driven by continuous innovations in bronchoscopes, oxygen therapy equipment, and pulmonary function testing systems.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 10.4% |
Driven by government initiatives via NHS to help enable early detection of lung disease, a growing usage of digital spirometry, and increasing outpatient pulmonary rehab programs, the UK pulmonology devices market is thriving. This will lead to a rise in demand for small diagnostic tools and wearable respiratory sensors, particularly for homecare and geriatric patients.
Government regulations that promote occupational lung disease screenings, as well as integrated primary care support, are also fuelling market growth. The rising penetration of such devices with remote respiratory consultations and self-management technology is likely to bolsters market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 9.6% |
The European Union pulmonology devices industry is being significantly propelled by public health initiatives focused on air quality, the growing elderly population, and increased access to pulmonary diagnostics. Germany, France, and Italy, among others, have been seen to emphasize the distribution of innovative broncho scopic devices, air capacity evaluators, and non-invasive inspiration-controlled frameworks.
European Union support for preventive care, digital health records and early intervention in respiratory diseases is driving demand. Moreover, the increasing utilization of automated diagnostic algorithms and portable pulmonary testing systems in outpatient setting is driving long-term adoption.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 10.0% |
The market for pulmonology devices in Japan is growing relatively moderately towards the upward trajectory, due to the increased incidence of respiratory complications in an aging population and technological supremacy in compact medical devices. Japan's hospitals are deploying high-sensitivity spirometers, flow sensors, and next-generation nebulization devices that are appropriate for older, frail patients with limited mobility.
The country’s migration to digitally connected respiratory systems and wireless monitoring is fuelling home-based care. Public health settings are also making preventive screenings for occupational lung conditions and advanced pulmonary imaging platforms, part of routine practice.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 9.3% |
The South Korea pulmonology devices market is growing strongly, supported by increase in chronic and pollution-related lung diseases as well as fast transition to telehealth enabled diagnostic tools. The high-tech hospitals of South Korea are employing AI-driven imaging and bronchoscopy devices and mobile respiratory health services.
Government initiatives to increase access to home medical devices and promote awareness of respiratory disease are driving the use of smart inhalers, oxygen concentrators and wearable monitors. Local advances in digital diagnostics and cloud-connected-once-daily (SDDs) are also disrupting the care ecosystem
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 10.2% |
With the rising cases of respiratory diseases worldwide, the pulmonology devices market is on a steady path of expansion, spurred on by factors such as population aging, smoking trends, air pollution, and rising awareness of chronic lung disorders. These devices meet diagnostic, therapeutic, and monitoring needs for an array of indications such as asthma, lung cancer, and sleep apnea.
Chronic obstructive pulmonary disease (COPD) is leading the indication segment among the key disease areas due to its wide global prevalence and the need for continuous respiratory care. On the basis of services delivery, hospitals continue to be the leading end user, providing access to advanced pulmonology technologies, critical care units, and multidisciplinary expertise. Collectively, these segments define the demand curve for pulmonology devices but also where innovation will go in respiratory care ecosystems.
Pulmonary device manufacturers target increased patient comfort, data connectivity, and clinical accuracy due to a growing emphasis in healthcare systems on early intervention and integrated care pathways. Hospitals are incubators for innovation, incorporating the latest technology in imaging, bronchoscopy, and ventilatory support.
On the other hand, COPD management is one of the strongest verticals that pushes the need for long-lasting and reliable respiratory solutions beyond episodic care in the market, making pulmonology devices a mainstay in and out of the acute environment.
| Indication Type | Market Share (2025) |
|---|---|
| COPD | 48.2% |
The indication with the largest segment share is by far the most common of these, driven by an aging population (especially among current and former long-term smokers). Scientific advances underscoring the need for consistent diagnostic monitoring and respiratory support include the progressive lung disease that restricts airflow and hinders respiration.
Devices like spirometers, nebulizers, portable oxygen concentrators and other non-invasive ventilators are key to symptom management, halting disease progression and preventing hospitalizations. These devices undergird home-based therapies, pulmonary rehabilitation, and emergency care, and prove vital to qualitative long-term management of COPD.
By providing advanced imaging and pulmonary function testing to measure lung capacity, healthcare providers can track individual COPD patients’ progress and adjust treatment plans accordingly. Wearable respiratory monitors and mobile connected devices make it possible to track symptoms in real time and even to intervene remotely.
Drug developers and device manufacturers continue to work together to develop integrated solutions that include drug delivery and respiratory diagnostics. As governments and public health agencies increasingly undertake COPD awareness programs and invest in chronic care infrastructure, demand for pulmonology devices in this application will continue to be strong and steady.
| End User | Market Share (2025) |
|---|---|
| Hospitals | 55.6% |
Airway pressure devices are dominating the end user segment in the pulmonology devices segment, with hospitals leading the pack, as they provide high-acuity respiratory care to patients with an array of acute and chronic lung conditions.
Armed with ICUs, emergency departments, and specialized pulmonary wards, hospitals are utilizing a plethora of devices from Bronchoscopy systems, mechanical ventilators, and oxygen therapy equipment to advanced imaging solutions. Such settings facilitate multidisciplinary working between pulmonologists, respiratory therapists, and critical care groups, paving the way for improved outcomes through coordination of care based on best practices.
Hospitals are also where early diagnosis and intervention take place, as well as providing support to patients with COPD, lung cancer, sleep disorders and obstruction of airways requires trained personnel and supportive infrastructure.
They perform pulmonary function tests, imaging scans and biopsies in the process. Hospitals continue to adopt smart, connected pulmonology devices that help streamline workflow and improve monitoring of patients, with increasing admissions for respiratory illnesses and due to increased respiratory monitoring. As public and private hospitals seek to expand respiratory care service lines, they will continue to drive the devices’ use and purchase, which will be central in the market’s future growth.
Pulmonology devices are a crucial part of the medical devices market and continues to be one of an innovative segments in the industry, with the growth of the market is attributed to the growing global burden of respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), lung cancer, sleep apnea, etc.
The strategic agenda for key players is centered on portable & connected devices, AI-assistive imaging, minimally invasive interventions, and home-infused respiratory monitoring. The market includes medtech giants, specialty respiratory companies and hospital equipment suppliers that help support critical care, outpatient management and pulmonary rehabilitation programs.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 20-24% |
| Philips Respironics (Koninklijke Philips N.V.) | 15-19% |
| Vyaire Medical, Inc. | 12-16% |
| Olympus Corporation | 8-12% |
| ResMed Inc. | 5-9% |
| Other Companies (combined) | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic plc | Released super Dimension™ navigation system for electromagnetic bronchoscopy in early lung cancer diagnosis in 2024, enhancing minimally invasive tissue access. |
| Philips Respironics | Launched Dream Station 2 Auto CPAP Advanced in 2025, combining connected therapy for sleep apnea with remote patient monitoring. |
| Vyaire Medical, Inc. | Introduced new Vyntus™ SPIRO PC spirometry platform in 2024, offering real-time lung function analysis and EMR integration. |
| Olympus Corporation | Expanded its EVIS X1 bronchoscopy imaging platform in 2024, targeting enhanced visualization and biopsy accuracy in pulmonary diagnostics. |
| ResMed Inc. | Debuted Air Curve™ 11 bilevel devices for complex sleep apnea therapy in 2025, integrating cloud-based compliance tracking and patient engagement. |
Key Company Insights
Medtronic plc
Medtronic leads in interventional pulmonology, offering advanced navigation and biopsy solutions that improve early detection and diagnosis of lung malignancies.
Philips Respironics
Philips is a key player in sleep and respiratory care, delivering connected devices and cloud-linked therapy platforms for home-based management of obstructive sleep apnea and COPD.
Vyaire Medical, Inc.
Vyaire specializes in diagnostic pulmonary devices, including spirometry and gas exchange systems, used in both hospital-based labs and primary care settings.
Olympus Corporation
Olympus is a leader in pulmonary endoscopy, offering high-definition bronchoscopes and AI-assisted imaging tools to support accurate lung disease detection.
ResMed Inc.
ResMed excels in digital respiratory solutions, combining non-invasive ventilation (NIV) with patient-centered platforms to improve chronic respiratory care outcomes.
Other Key Players (30-40% Combined)
Several other companies contribute to the pulmonology devices market, focusing on wearable diagnostics, portable nebulizers, airway management, and hospital automation:
The overall market size for the pulmonology devices market was USD 1,703.2 million in 2025.
The pulmonology devices market is expected to reach USD 4,417.7 million in 2035.
The increasing prevalence of chronic respiratory conditions, rising demand for effective COPD management, and growing hospital-based adoption of advanced pulmonology devices fuel the pulmonology devices market during the forecast period.
The top 5 countries driving the development of the pulmonology devices market are the USA, UKq, European Union, Japan, and South Korea.
COPD management and hospital-based adoption lead market growth to command a significant share over the assessment period.
Anti-hyperglycemic Agents Market: Growth, Trends, and Assessment for 2025 to 2035
At Home Heart Health Testing Market Analysis - Size & Industry Trends 2025 to 2035
Eyelid Scrub Market Analysis & Forecast by Product, Application and Region 2025 to 2035
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Pulmonology Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
